These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. Cavallone L; Arcand SL; Maugard C; Ghadirian P; Mes-Masson AM; Provencher D; Tonin PN BMC Cancer; 2008 Apr; 8():96. PubMed ID: 18402691 [TBL] [Abstract][Full Text] [Related]
3. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Wang X; Pankratz VS; Fredericksen Z; Tarrell R; Karaus M; McGuffog L; Pharaoh PD; Ponder BA; Dunning AM; Peock S; Cook M; Oliver C; Frost D; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Houdayer C; ; Hogervorst FB; Hooning MJ; Ligtenberg MJ; ; Spurdle A; Chenevix-Trench G; ; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Domchek SM; Nathanson KL; Rebbeck TR; Singer CF; Gschwantler-Kaulich D; Dressler C; Fink A; Szabo CI; Zikan M; Foretova L; Claes K; Thomas G; Hoover RN; Hunter DJ; Chanock SJ; Easton DF; Antoniou AC; Couch FJ Hum Mol Genet; 2010 Jul; 19(14):2886-97. PubMed ID: 20418484 [TBL] [Abstract][Full Text] [Related]
4. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Mulligan AM; Couch FJ; Barrowdale D; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Robson M; Sherman M; Spurdle AB; Wappenschmidt B; Lee A; McGuffog L; Healey S; Sinilnikova OM; Janavicius R; Hansen Tv; Nielsen FC; Ejlertsen B; Osorio A; Muñoz-Repeto I; Durán M; Godino J; Pertesi M; Benítez J; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Bonanni B; Viel A; Pasini B; Papi L; Ottini L; Savarese A; Bernard L; Radice P; Hamann U; Verheus M; Meijers-Heijboer HE; Wijnen J; Gómez García EB; Nelen MR; Kets CM; Seynaeve C; Tilanus-Linthorst MM; van der Luijt RB; van Os T; Rookus M; Frost D; Jones JL; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Cook J; Donaldson A; Dorkins H; Gregory H; Eason J; Houghton C; Barwell J; Side LE; McCann E; Murray A; Peock S; Godwin AK; Schmutzler RK; Rhiem K; Engel C; Meindl A; Ruehl I; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Kast K; Preisler-Adams S; Varon-Mateeva R; Schoenbuchner I; Fiebig B; Heinritz W; Schäfer D; Gevensleben H; Caux-Moncoutier V; Fassy-Colcombet M; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Hardouin A; Berthet P; Muller D; Fricker JP; Mortemousque I; Pujol P; Coupier I; Lebrun M; Kientz C; Longy M; Sevenet N; Stoppa-Lyonnet D; Isaacs C; Caldes T; de la Hoya M; Heikkinen T; Aittomäki K; Blanco I; Lazaro C; Barkardottir RB; Soucy P; Dumont M; Simard J; Montagna M; Tognazzo S; D'Andrea E; Fox S; Yan M; Rebbeck T; Olopade O; Weitzel JN; Lynch HT; Ganz PA; Tomlinson GE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet M; Bhatia J; Kauff N; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Mai PL; Greene MH; Imyanitov E; O'Malley FP; Ozcelik H; Glendon G; Toland AE; Gerdes AM; Thomassen M; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Soller M; Henriksson K; Wachenfeldt vA; Arver B; Stenmark-Askmalm M; Karlsson P; Ding YC; Neuhausen SL; Beattie M; Pharoah PD; Moysich KB; Nathanson KL; Karlan BY; Gross J; John EM; Daly MB; Buys SM; Southey MC; Hopper JL; Terry MB; Chung W; Miron AF; Goldgar D; Chenevix-Trench G; Easton DF; Andrulis IL; Antoniou AC; ; ; ; ; ; ; ; Breast Cancer Res; 2011; 13(6):R110. PubMed ID: 22053997 [TBL] [Abstract][Full Text] [Related]
5. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Jakubowska A; Rozkrut D; Antoniou A; Hamann U; Lubinski J Breast Cancer Res Treat; 2010 Jun; 121(3):639-49. PubMed ID: 19876733 [TBL] [Abstract][Full Text] [Related]
12. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639 [TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156 [TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875 [TBL] [Abstract][Full Text] [Related]
16. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Chenevix-Trench G; Milne RL; Antoniou AC; Couch FJ; Easton DF; Goldgar DE; Breast Cancer Res; 2007; 9(2):104. PubMed ID: 17466083 [TBL] [Abstract][Full Text] [Related]
18. The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Lång A; Palmebäck Wegman P; Wingren S Oncol Rep; 2009 Sep; 22(3):575-9. PubMed ID: 19639206 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175 [TBL] [Abstract][Full Text] [Related]